|Mr. Carsten Hellmann||Pres, CEO & Member of Management Board||14.45M||N/A||1964|
|Mr. Søren Jelert||Group CFO, Exec. VP & Member of Management Board||6.14M||N/A||1972|
|Mr. Henrik Jacobi||Exec. VP of R&D and Member of Board of Management||5.37M||N/A||1965|
|Mr. Søren Daniel Niegel||Exec. VP of Commercial Operations & Member of Management Board||5.34M||N/A||1971|
|Ms. Katja Barnkob Thalund||Project Director of Global CMC Devel. & Employee-elected Director||300k||N/A||1969|
|Mr. Per Plotnikof||VP of Corp. Communications, Investor Relations & Strategic Planning and Head of IR||N/A||N/A||N/A|
|Prof. Hendrik Kees Kam Nolte M.D., Ph.D.||Sr. VP of Research & Devel. - North America and International Markets||N/A||N/A||N/A|
|Mr. Christian G. Houghton||Head of Product Supply||N/A||N/A||N/A|
|Mr. Miles Guralnick||Pres of ALK Abelló Source Materials Inc||N/A||N/A||N/A|
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
ALK-Abelló A/S’s ISS governance QualityScore as of 1 October 2022 is 3. The pillar scores are Audit: 1; Board: 4; Shareholder rights: 9; Compensation: 2.